Primary composite endpoint at 12 months of serum alkaline phosphatase and bilirubin was met by 61.7% of patients treated with seladelpar 10 mg vs. 20.0% of placebo treated patients (p<0.0001)
Normalization of alkaline phosphatase at 12 months was achieved by 25.0% of patients treated with seladelpar vs. 0% on placebo (p<0.0001)
In patients having moderate-to-severe itch at baseline, the seladelpar treated group improved their pruritus at 6 months compared to those in the placebo group (p<0.005)
Safety and tolerability were comparable between placebo and seladelpar groups and consistent with previous studies
CymaBay will hold a conference call to discuss these results today at 8:00 a.m. ET
CymaBay will host a conference call today, Thursday, September 7 at 8:00 a.m. ET to discuss the topline results from this study. To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13741034. To access the live and archived webcast of the conference call, go to the Investors section of the CymaBay website at http://ir.cymabay.com/events. A slide presentation to be referenced on the conference call will be available in the Investors section of the CymaBay website shortly before the call.
https://finance.yahoo.com/news/cymabays-seladelpar-achieves-high-statistical-110000681.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.